Addiction
-
Regulation of electronic cigarettes has moved to the top of the addiction policy agenda, as demonstrated by the recent focus across the United Kingdom on introducing age-of-sale restrictions. However, the views of those affected by such regulation remain largely unexplored. This paper presents the first detailed qualitative exploration of adolescents' perceptions of existing, and opinions about potential e-cigarette regulation. ⋯ In focus group discussions, a sample of UK adolescents exposed to particular communications about e-cigarettes supported strict regulation of e-cigarettes, including banning sales to minors and use in indoor public areas.
-
Electronic cigarettes are currently polarizing professional opinion. Some public health experts regard them as an effective smoking cessation aid and a vital means of reducing active and passive smoking, while others regard them as another attempt by the tobacco industry to create new customers and addicts. These different attitudes unsurprisingly yield different conclusions regarding both the appropriate regulation of e-cigarettes and the ethical status of research funded by, or conducted in, cooperation with the tobacco industry. ⋯ Journals that currently refuse to publish findings from studies linked to tobacco companies have no reason to make an exception in the case of e-cigarettes.
-
Randomized Controlled Trial
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
To examine the safety and effectiveness of buprenorphine + naloxone sublingual tablets (BUP, as Suboxone(®) ) provided after administration of extended-release injectable naltrexone (XR-NTX, as Vivitrol(®) ) to reduce cocaine use in participants who met DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse. ⋯ Buprenorphine + naloxone, used in combination with naltrexone, may be associated with reductions in cocaine use among people who meet DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse.
-
Fatal outcome of opioid overdose, once detected, is preventable through timely administration of the antidote naloxone. Take-home naloxone provision directly to opioid users for emergency use has been implemented recently in more than 15 countries worldwide, albeit mainly as pilot schemes and without formal evaluation. This systematic review assesses the effectiveness of take-home naloxone, with two specific aims: (1) to study the impact of take-home naloxone distribution on overdose-related mortality; and (2) to assess the safety of take-home naloxone in terms of adverse events. ⋯ Take-home naloxone programmes are found to reduce overdose mortality among programme participants and in the community and have a low rate of adverse events.